LYEL
NASDAQ · Biotechnology
Lyell Immunopharma Inc
$14.86
-0.14 (-0.93%)
Financial Highlights (FY 2026)
Revenue
51.0K
Net Income
-389,787,161
Gross Margin
—
Profit Margin
-762,355.6%
Rev Growth
-92.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -748,344.4% | -673,510.5% | -16.0% | -15.0% |
| Profit Margin | -762,355.6% | -724,237.8% | -14.9% | -15.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 51.0K | 677.9K | 107.82M | 110.08M |
| Gross Profit | — | — | 31.94M | 32.61M |
| Operating Income | -381,505,995 | -4,565,896,216 | -17,264,565 | -16,469,755 |
| Net Income | -389,787,161 | -4,665,005,916 | -16,079,673 | -17,508,845 |
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -748,344.4% | -673,510.5% | -16.0% | -15.0% |
| Profit Margin | -762,355.6% | -724,237.8% | -14.9% | -15.9% |
| Rev Growth | -92.5% | -92.5% | +2.1% | -2.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 170.75M | 218.79M |
| Total Equity | — | — | 336.15M | 314.14M |
| D/E Ratio | — | — | 0.51 | 0.70 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -366,234,172 | -4,626,628,502 | -19,078,562 | -20,059,530 |
| Free Cash Flow | — | — | -8,704,547 | -8,409,186 |